In general, our results reported HDAC9‐mediated CaM deacetylation induced memory impairment in AD, and discovered that abnormally reduced plasma CaM acetylation may be a new early diagnostic marker for AD, and indicated that HDAC9 or CaM acetylation may become potential therapeutic targets for AD. This evidence concerns the gene HDAC9 and memory impairment.